BLADE AIR MOBILITY INC (NASDAQ:BLDE) Reports Q2 2025 Earnings: Revenue Beats, Losses Narrow
Blade Air Mobility Inc. released its second-quarter 2025 earnings, showing mixed but largely positive results compared to analyst expectations. The company, which specializes in urban air mobility and medical organ transport services, reported revenue growth and a reduced net loss, contributing to a modest pre-market uptick in its stock price.
Key Financial Highlights
- Revenue Surpasses Estimates: Blade reported Q2 revenue of $70.8 million, exceeding analyst expectations of $65.36 million, marking a 17.6% year-over-year increase in its medical segment.
- Narrower Losses: The company posted a net loss of $3.7 million, an improvement of $7.6 million compared to the prior year. Adjusted earnings per share (EPS) came in at -$0.05, slightly worse than the estimated -$0.0449.
- Medical Segment Growth: The medical transportation business, which includes organ transplant logistics, continued to be a strong driver, reinforcing Blade’s dual focus on passenger and medical services.
Market Reaction
Following the earnings release, BLDE shares saw a pre-market gain of approximately 0.9%, suggesting cautious optimism among investors. Over the past month, the stock has risen 5.7%, though it remains relatively flat on a weekly basis. The market’s reaction appears to reflect relief at the revenue beat and improved profitability, despite the slight miss on EPS.
Forward-Looking Estimates
Analysts project the following for Blade Air Mobility:
- Q3 2025 Revenue Estimate: $81.61 million
- Q3 2025 EPS Estimate: $0.0326 (indicating potential profitability)
- Full-Year 2025 Revenue Estimate: $263.09 million
- Full-Year 2025 EPS Estimate: -$0.114
While the company did not provide explicit guidance in its press release, the current analyst estimates suggest expectations of continued revenue growth and a potential shift toward profitability in the near term.
Press Release Summary
The earnings announcement highlighted:
- Strong performance in medical organ transport services.
- Cost reductions contributing to a significantly lower net loss.
- Continued expansion in both U.S. and European markets.
For a deeper dive into Blade’s earnings and future estimates, see the full breakdown here.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research or consult a financial advisor before making any decisions.
